Panotile (Fludrocortisone Acetate, Neomycin Sulfate, Polymyxin B Sulfate, Lidocaine Hydrochloride)

Fludrocortisone provides anti‑inflammatory activity by modulating glucocorticoid receptors, while neomycin and polymyxin B act as antibiotics that inhibit bacterial protein synthesis and disrupt cell membranes. Lidocaine adds rapid local anaesthesia by blocking sodium channels, which together reduce infection, swelling and pain in the ear.

The specific dose and frequency of Panotile are determined by the prescribing clinician based on the severity of the condition, patient age and ear status. Patients should follow the healthcare professional’s instructions and not alter the regimen without medical advice.

Safety data for Panotile in pregnancy and lactation are limited. The prescriber should weigh the potential benefits against any possible risks to the fetus or infant. If treatment is essential, it may be used under close medical supervision.

To request Panotile, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Panotile combines a corticosteroid, two antibiotics and a local anaesthetic in a single formulation, offering anti‑inflammatory, antimicrobial and analgesic effects simultaneously. Many alternative ear drops contain only one antibiotic or lack a steroid, which may require additional products to achieve comparable symptom control.

Panotile should be stored at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid freezing. If the solution appears discoloured or contaminated, discard it.

Panotile is applied as ear drops directly into the affected ear(s) while the patient’s head is tilted to expose the canal. The prescribed number of drops is instilled, the head is held in position for a few minutes to allow absorption, and the procedure is repeated according to the clinician’s schedule.

Serious risks include allergic contact dermatitis, ototoxicity leading to hearing loss or balance disturbances, and rare systemic toxicity such as nephrotoxicity from absorbed aminoglycosides. Patients should report any severe rash, sudden hearing changes, dizziness or signs of kidney impairment promptly.

Panotile should be avoided in individuals with known hypersensitivity to any of its components, in patients with a perforated tympanic membrane unless specifically directed by a physician, and in those receiving other ototoxic medications without careful monitoring. Pediatric use requires special consideration by a healthcare professional.